Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Betsy Goodfellow | May 3, 2023 | News story | Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab 

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) being treated with lebrikizumab.

The analysis showed patients treated with lebrikizumab who were assessed at 16 weeks experienced either improved or cleared face or hand dermatitis. Further analysis also demonstrated that the drug’s results were stable and long-lasting after a year of treatment in patients with moderate-to-severe AD, also known as eczema.

Full results from the ADvocate and ADhere studies were presented at the 5th annual Revolutionizing Atopic Dermatitis (RAD) Congress.

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor, which is currently being studied in adult and adolescent patients over the age of 12 with moderate-to-severe AD. Final regulatory decisions are expected in the US and EU by the end of 2023.

Jenny Murase, MD, associate clinical professor of Dermatology at the University of California San Francisco, US, director of Medical Dermatology Consultative Services and Patch Testing for the Palo Alto Foundation Medical Group and lead author on the face and hand analysis, commented: “The fluctuating symptoms and unpredictable nature of AD, along with limited medicines that can adequately manage long-term uncontrolled symptoms, represent major challenges in the treatment of this chronic disease. These data provide valuable insights into how lebrikizumab may help improve clinical outcomes by providing improvements in dermatitis on the face and hands, which can be difficult to treat, and offer long-term disease control for patients.”

Betsy Goodfellow

Related Content


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …


Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C …

Latest content